A study on the preparation and anti-tumor efficacy of bovine serum albumin nanospheres containing 5-fluorouracil

Drug Development and Industrial Pharmacy

Volumn 28, Issue 9, 2002, Pages 1171-1179

  Santhi, K ^a   Dhanaraj, S A ^a   Joseph, Vinod ^a   Ponnusankar, S ^a   Suresh, B ^a  

^a JSS COLLEGE OF PHARMACY   (India)

Author keywords

5 Fluorouracil; Anti tumor study; Bovine serum albumin; Cytotoxicity; In vitro release; Nanospheres

Indexed keywords

BOVINE SERUM ALBUMIN; DODECYL SULFATE SODIUM; FLUOROURACIL; GLUCOSE; MANNITOL; NANOPARTICLE; SURFACTANT; ANTINEOPLASTIC ANTIMETABOLITE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER; COLLOID; CONCENTRATION (PARAMETERS); CRYOPROTECTION; CYTOTOXICITY; DRUG EFFICACY; DRUG RELEASE; FREEZE DRYING; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; PARTICLE SIZE; PH; ANIMAL; CELL CULTURE; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; NANOTECHNOLOGY;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; FLUOROURACIL; FREEZE DRYING; HYDROGEN-ION CONCENTRATION; MICE; NANOTECHNOLOGY; PARTICLE SIZE; SERUM ALBUMIN, BOVINE; SURFACE-ACTIVE AGENTS; TUMOR CELLS, CULTURED;

EID: 0036414516     PISSN: 03639045     EISSN: None     Source Type: Journal    
DOI: 10.1081/DDC-120014584     Document Type: Article

References (20)

1. Couvreur, P.; Roblet-treupel, L.; Poupon, F. Adv. Drug Del. Rev. 1990, 5, 210.
2. Jones, R.T.; Gelatin; structure and manufacture. In Hard Gelatin Development and Technology, Ridgeway, K., Ed.; Pharmaceutical Press: London, 1987; 13-30.
3. Oppenheim, R.C.; Stewart, N.F. Drug Dev. Ind. Pharm. 1979, 5, 585.
4. Forni, F.; Leo, E.; Vandelli, A. Int. J. Pharm. 1997, 155, 76.
5. Calabresi, P.; Chabner, A.B. Chemotherapy of neoplastic disease. In Goodman and Gilman's Pharmacological Basis of Therapeutics, 8th Ed., 1202-1279.
6. Swarbrick, J.; Boylan, C.J.; Kreuter, J. Nanoparticles. In Encyclopedia of Pharmaceutical Technology; Marcel Dekker: New York, 1994; 165-190.
7. Couvreur, P.; Vauthier, C. Int. J. Pharm. 1991, 168, 507.
8. Sugibayashi, K.; Morimoto, Y.; Nagai, T.; Kato, Y. Chem. Pharm. Bull. 1977, 12, 3436.
9. Lin, A.; Coombes, G.A.; Davies, M.C.; Davis, S.S.; Illum, L. J. Drug Target. 1993, 1, 237-243.
10. United States Pharmacopoeia, 24th Revision, United States Pharmacopoeial Convention Inc., Rockville, MD; 1820-1823W.
11. Mbela, T.K.; Poupaerb, J.H.; Dumont, P.; Haemers, A. Int. J. Pharm. 1993, 92, 73.
12. Wung, W.E.; Howell, S.B. Clin. Chem. 1980, 26, 1704.
13. Ohya, Y.; Shiratani, M.; Kobayashi, H.; Ouchi, T. Pure Appl. Chem. A 1994, 31(5), 634.
14. Yoshioka, T.; Hashida, M.; Muranish, S.; Sezaki, H. Int. J. Pharm. 1981, 8, 134.
15. Tabata, Y.; Uno, K.; Ikada, Y.; Muramatsu, S. Jpn. J. Cancer Res. 1988, 79, 636.
16. Babu, T.; Kuttan, D.; Jose Padikkala, G. J. Ethno. Pharmacol. 1995, 48, 53.
17. Oppenheim, R.C. Nanoparticulate drug delivery systems based on gelatin and albumin. In Polymeric Nanoparticles as Drug Carriers for Antitumor Agents; CRC Press: Boca Raton, FL, 1986; 27.
18. Marty, J.J.; Oppenheim, R.C.; Speiser, P.P. Pharm. Acta Helv. 1978, 53, 17-23.
19. Oppenheim, R.C. Int. J. Pharm. 1981, 8, 226.
20. Roy, D.; Guillon, X.; Lescure, F.; Courreur, P.; Bru, N.; Breton, P. Int. J. Pharm. 1997, 148, 267.